Search Results

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022.

Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.

Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.

Cortexyme, Inc. today provided a business update and announced key milestones for 2022.

Cortexyme said it plans to provide additional updates pending further talks with the FDA.

Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases.

Cortexyme, Inc. today announced that its board of directors has appointed Christopher Lowe, the company’s chief operating officer and chief financial officer, as interim chief executive.